Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Goran Klintmalm

Transplant Surgery Dallas, TX Medical Doctor

NPI 1245260280 CMS profile 237419

3410 Worth St, Suite 950, Dallas, TX 75246

Open in the dashboard

General payments

$87,865

10 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Goran Klintmalm of Dallas, TX is reported in the CMS Open Payments database as having received $87,865 across 10 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Transplant Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $44 1
2023 General $44,311 3
2022 General $17,091 2
2021 General $26,250 1
2020 General $15 1
2019 General $153 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Goran Klintmalm
  • Transplant Surgery median
  • Middle half of Transplant Surgery
  • National median

In program year 2025, general payments to Goran Klintmalm were reported at $0. Among 555 Transplant Surgery profiles paid that year, the median was $421 and the middle half received between $116 and $2,169.

Show as a table
Year Goran Klintmalm Transplant Surgery median Middle half National median
2019 $153 $203 $77–$1,249 $163
2020 $15 $149 $52–$1,366 $114
2021 $26,250 $168 $73–$2,008 $132
2022 $17,091 $213 $94–$1,464 $149
2023 $44,311 $262 $93–$1,458 $160
2024 $44 $354 $126–$2,252 $164
2025 $0 $421 $116–$2,169 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Immucor, Inc. $87,603 5 payments
  2. Veloxis Pharmaceuticals, Inc. $144 3 payments
  3. Genzyme Corporation $103 1 payment
  4. Novartis Pharmaceuticals Corporation $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Consulting Fee $78,717 3 payments
  2. Travel and Lodging $8,691 1 payment
  3. Food and Beverage $456 6 payments
Products named General payments · program years 2019–2024
  1. kSort $44,067 1 payment
  2. kSORT Kidney Transplant $26,250 1 payment
  3. THYMOGLOBULIN $103 1 payment
  4. ENVARSUS Transplantation $94 2 payments
  5. Envarsus Immunosuppressant $50 1 payment
  6. Envarsus Immunosuppressant $50 1 payment
  7. ENTRESTO $15 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

10 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Transplant Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record